Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.23
BAYRY's Cash to Debt is ranked higher than
51% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. BAYRY: 0.23 )
BAYRY' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.23

Equity to Asset 0.36
BAYRY's Equity to Asset is ranked higher than
50% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. BAYRY: 0.36 )
BAYRY' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.46
Current: 0.36

0.21
0.46
F-Score: 6
Z-Score: 2.55
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 10.48
BAYRY's Operating margin (%) is ranked higher than
76% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.93 vs. BAYRY: 10.48 )
BAYRY' s 10-Year Operating margin (%) Range
Min: -4.21   Max: 12.29
Current: 10.48

-4.21
12.29
Net-margin (%) 7.94
BAYRY's Net-margin (%) is ranked higher than
76% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.07 vs. BAYRY: 7.94 )
BAYRY' s 10-Year Net-margin (%) Range
Min: -4.41   Max: 14.56
Current: 7.94

-4.41
14.56
ROE (%) 15.33
BAYRY's ROE (%) is ranked higher than
91% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. BAYRY: 15.33 )
BAYRY' s 10-Year ROE (%) Range
Min: -10.32   Max: 28.18
Current: 15.33

-10.32
28.18
ROA (%) 6.21
BAYRY's ROA (%) is ranked higher than
81% of the 748 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. BAYRY: 6.21 )
BAYRY' s 10-Year ROA (%) Range
Min: -3.37   Max: 9.18
Current: 6.21

-3.37
9.18
ROC (Joel Greenblatt) (%) 33.44
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.91 vs. BAYRY: 33.44 )
BAYRY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6.8   Max: 34.73
Current: 33.44

-6.8
34.73
Revenue Growth (%) 4.60
BAYRY's Revenue Growth (%) is ranked higher than
67% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. BAYRY: 4.60 )
BAYRY' s 10-Year Revenue Growth (%) Range
Min: -10.6   Max: 14
Current: 4.6

-10.6
14
EBITDA Growth (%) 2.40
BAYRY's EBITDA Growth (%) is ranked higher than
67% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. BAYRY: 2.40 )
BAYRY' s 10-Year EBITDA Growth (%) Range
Min: -17.7   Max: 18.3
Current: 2.4

-17.7
18.3
EPS Growth (%) 35.00
BAYRY's EPS Growth (%) is ranked higher than
90% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. BAYRY: 35.00 )
BAYRY' s 10-Year EPS Growth (%) Range
Min: -19.1   Max: 41.4
Current: 35

-19.1
41.4
» BAYRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BAYRY Guru Trades in Q3 2013

Ken Fisher 86,861 sh (+2.85%)
» More
Q4 2013

BAYRY Guru Trades in Q4 2013

Ken Fisher 85,386 sh (-1.7%)
» More
Q1 2014

BAYRY Guru Trades in Q1 2014

Ken Fisher 270,713 sh (+217.05%)
» More
Q2 2014

BAYRY Guru Trades in Q2 2014

Ken Fisher 2,302,369 sh (+750.48%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2012-12-31 Reduce -21.2%0.21%$83.28 - $96.38 $ 128.7444%2044656
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.40
BAYRY's P/E(ttm) is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.40 vs. BAYRY: 23.40 )
BAYRY' s 10-Year P/E(ttm) Range
Min: 8.67   Max: 90.16
Current: 23.4

8.67
90.16
P/B 4.30
BAYRY's P/B is ranked higher than
64% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. BAYRY: 4.30 )
BAYRY' s 10-Year P/B Range
Min: 0.93   Max: 4.45
Current: 4.3

0.93
4.45
P/S 2.10
BAYRY's P/S is ranked higher than
80% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. BAYRY: 2.10 )
BAYRY' s 10-Year P/S Range
Min: 0.45   Max: 2.17
Current: 2.1

0.45
2.17
PFCF 28.80
BAYRY's PFCF is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BAYRY: 28.80 )
BAYRY' s 10-Year PFCF Range
Min: 4.4   Max: 72.98
Current: 28.8

4.4
72.98
EV-to-EBIT 18.82
BAYRY's EV-to-EBIT is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.81 vs. BAYRY: 18.82 )
BAYRY' s 10-Year EV-to-EBIT Range
Min: 7.2   Max: 24.6
Current: 18.82

7.2
24.6
PEG 8.70
BAYRY's PEG is ranked higher than
77% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 367.50 vs. BAYRY: 8.70 )
BAYRY' s 10-Year PEG Range
Min: 1.54   Max: 9.76
Current: 8.7

1.54
9.76
Shiller P/E 35.20
BAYRY's Shiller P/E is ranked higher than
85% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BAYRY: 35.20 )
BAYRY' s 10-Year Shiller P/E Range
Min: 13.49   Max: 50.98
Current: 35.2

13.49
50.98
Current Ratio 1.43
BAYRY's Current Ratio is ranked higher than
56% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. BAYRY: 1.43 )
BAYRY' s 10-Year Current Ratio Range
Min: 1   Max: 2.13
Current: 1.43

1
2.13
Quick Ratio 0.93
BAYRY's Quick Ratio is ranked higher than
53% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. BAYRY: 0.93 )
BAYRY' s 10-Year Quick Ratio Range
Min: 0.64   Max: 1.44
Current: 0.93

0.64
1.44

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.60
BAYRY's Dividend Yield is ranked higher than
75% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. BAYRY: 1.60 )
BAYRY' s 10-Year Dividend Yield Range
Min: 1.92   Max: 3.93
Current: 1.6

1.92
3.93
Dividend Payout 1.80
BAYRY's Dividend Payout is ranked higher than
79% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BAYRY: 1.80 )
BAYRY' s 10-Year Dividend Payout Range
Min: 1.23   Max: 2.1
Current: 1.8

1.23
2.1
Dividend growth (3y) -100.00
BAYRY's Dividend growth (3y) is ranked higher than
59% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. BAYRY: -100.00 )
BAYRY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -4.6
Current: -100

Yield on cost (5-Year) 1.60
BAYRY's Yield on cost (5-Year) is ranked higher than
71% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.39 vs. BAYRY: 1.60 )
BAYRY' s 10-Year Yield on cost (5-Year) Range
Min: 1.92   Max: 3.93
Current: 1.6

1.92
3.93

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.50
BAYRY's Price/DCF (Projected) is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BAYRY: 1.50 )
BAYRY' s 10-Year Price/DCF (Projected) Range
Min: 0.67   Max: 2.1
Current: 1.5

0.67
2.1
Price/Median PS Value 1.60
BAYRY's Price/Median PS Value is ranked higher than
60% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. BAYRY: 1.60 )
BAYRY' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 3.79
Current: 1.6

0.26
3.79
Earnings Yield (Greenblatt) 5.30
BAYRY's Earnings Yield (Greenblatt) is ranked higher than
75% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. BAYRY: 5.30 )
BAYRY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.1   Max: 13.9
Current: 5.3

4.1
13.9
Forward Rate of Return (Yacktman) 8.97
BAYRY's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. BAYRY: 8.97 )
BAYRY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.2   Max: 18.3
Current: 8.97

-8.2
18.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BAYN.Germany, BAYA.Germany, BAY.Italy, BAY.Spain
Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products (46% of sales), material sciences (36% of sales), and crop sciences (18% of sales). Bayer's over-the-counter health-care product division is the third-largest in the world.
» More Articles for OTCPK:BAYRY

Headlines

Articles On GuruFocus.com
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Ken Fisher for Forbes - 5 Fantastic Stocks for Fretters Jun 26 2013 
Pfizer: A Strong Stock for 2013 Apr 20 2012 
Maxygen Inc. (MAXY): A Magic Formula Stock to Avoid Feb 05 2009 


More From Other Websites
The Morning Download: IT Is Transforming Heavy Industry Around the World Aug 01 2014
Bayer Earnings Grow Marginally Y/Y, New Products Encourage Jul 31 2014
Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema Jul 30 2014
Amgen Restructuring Plan, Q2 Earnings Send Stock Up Jul 30 2014
Merck, Pfizer Ramping R&D After Q2 Earnings Beat Jul 29 2014
Merck (MRK) Tops Q2 Earnings Expectations on Cost Cuts Jul 29 2014
Ken Fisher's Top Increases of the Second Quarter Jul 28 2014
Bayer/Amgen's Nexavar Does Not Show Resilience in Study Jul 25 2014
Evogene announces amendment to Bayer wheat agreement Jul 24 2014
Bayer Battles New Insecticide Research Affecting 20% of Sales Jul 23 2014
[video] 10 Highlights in U.S. Insecticide History From the Last 50 Years Jul 23 2014
Bayer/Regeneron Continue to Progress with Eylea Jul 22 2014
New Bayer plastic makes luggage lighter and more secure -- Travel more comfortably -- Andiamo... Jul 22 2014
Bayer MaterialScience brings magic to materials -- Global launch of INSQIN®: game changing solution... Jul 15 2014
Ceres licenses Persephone genome application to Bayer CropScience Jul 08 2014
Not intended for U.S. and UK Media -- Bayer and University of Oxford to Develop Novel Gynecological... Jul 03 2014
Regeneron Shares Jump as Sanofi Increases Stake Jul 02 2014
Functional clothing at the Soccer World Cup with materials from Bayer: -- Skin-tight energy storage... Jul 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide